3 news items
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
NUVL
16 May 24
," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
NUVL
9 May 24
," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
NUVL
8 Apr 24
demonstrated potency against a broad range of HER2 oncogenic alterations and selectivity over wild-type EGFR, in line with our goal of designing molecules
- Prev
- 1
- Next